

PRTN3

Native Human Proteinase 3

| | | | |
|---------------------------------|---|------------------|---------------|
| Catalog No. | CSI14825A CSI14825B | Quantity: | 25 µg 1 mg |
| Alternate Names: | PR-3, PR3, Myeloblastin, MBN, MBT, ACPA, C-ANCA, CANCA, NP4, P29, Wegener granulomatosis autoantigen, Azurophil Granule Protein 7, AGP7, Leukocyte Proteinase 3 | | |
| Description: | Proteinase 3 (PRTN3) is a human polymorphonuclear leukocyte serine proteinase that degrades elastin in vitro and has been shown to play a role in the pathogenesis of emphysema. PRTN3 is overexpressed in a variety of acute and chronic myeloid leukemia cells. Autoantibodies against PRTN3 are an obligate feature in the pathogenesis of Wegener's granulomatosis, a systemic autoimmune vasculitis. | | |
| Concentration: | Typically >0.5 mg/mL | | |
| Gene ID: | 5657 | | |
| Source: | Human Neutrophil | | |
| Formulation: | Liquid in 0.05 M Sodium Acetate pH 6.0 + 0.7 M NaCl | | |
| Purity: | >96% by SDS-PAGE. Multiple bands are observed. All are reactive in Western blot analysis. | | |
| Specific Activity: | Typically >0.05 U/mL @ 37°C | | |
| Unit Definition: | One unit will hydrolyze one micromole of Methoxy succinyl-alanine-alanine-proline-valine-p-nitroanilide per minute at 37°C and pH 7.5 | | |
| Storage & Stability: | Store at 2-4°C. 1 year. | | |
| Ethical Statement: | Non-Infectious Disease Certification: Non-reactive for HIV-1/HCV/HBV by NAT; HBsAg, HCV Ab, HIV-1&2 Ab and RPR by currently approved FDA methods. However, because no test method can offer complete assurance that infectious agents are absent, this material should be handled at Bio-Safety Level 2 (BSL 2) as recommended for potentially infectious human serum or blood specimen in the CCD/NIH manual "Biosafety in Microbiological and Biomedical Laboratories", 1999. | | |

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.